Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook

RenovoRx

12/08/2026 21:20

Overview
Targeted oncology device maker's Q2 2026 revenue rose 115% yr/yr to record $909,000
Company raised full-year 2026 revenue guidance to $3.75 mln-$4.25 mln
Active commercial cancer center customers grew to 21, up from 16 in Q1

Outlook
RenovoRx raises 2026 revenue guidance to $3.75 mln-$4.25 mln from $3.0 mln-$4.0 mln
Company expects Q3 revenue to exceed Q2 and set another record
RenovoRx anticipates reaching cash-flow break-even in Q4 2027 at $5 mln quarterly revenue run-rate

Result Drivers
CUSTOMER EXPANSION - Growth in active commercial cancer center customers and expansion of the commercial pipeline drove revenue gains
REPEAT UTILIZATION - Increased repeat ordering from existing customers contributed to sustained revenue growth
TRIAL SITE TRANSITIONS - Transition of Phase III TIGeR-PaC trial sites to commercial use expected to boost revenue in second half

Company press release: ID:nGNX45Ks15

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.06
 
Q2 Net Loss
 
$2.91 mln
 
Q2 Loss Per Basic Share
 
$0.06
 
Q2 Operating Expenses
 
$4.12 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 378.3% above its August 11 closing price of $1.15

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Legend Biotech Q2 revenue beats estimates on commercial expansion
Aug 12 - Israel's IceCure Medical H1 revenue rises on higher system, probe sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)